Genentech’s Tecentriq plus Avastin Reduced the Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study

Genentech announced new data from the Phase III IMbrave050 study that show Tecentriq® plus Avastin® demonstrated a statistically significant improvement in recurrence-free survival in people with HCC at high risk of disease recurrence following liver resection or ablation with curative intent.